Managing ICU Arrhythmias: Rapid Rate Control Strategies Using β1-Selective Agents

View this SCCM webcast recording for dynamic, case-driven discussions that dive into the complexities of managing new-onset atrial fibrillation in critically ill patients. Expert faculty will unpack the pharmacologic nuances of beta-antagonists in the ICU setting and deliver actionable insights to help you optimize hemodynamic stability when it matters most.

This webcast is supported by AOP Health.

Learning Objectives
• Apply evidence-based strategies in case-based scenarios for rate control in critically ill patients with new-onset atrial fibrillation to support safe and effective ICU management
• Explain the pharmacologic characteristics and mechanism of action of a β1-antagonist for the short-term reduction of ventricular rate in adult patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter

Subject Matter Experts:
Jean-Luc Fellahi, MD, PhD
Professor of Anaesthesiology and Critical Care
Louis Pradel University Hospital
Lyon, France

Michael R. Bristow, MD, PHD
Director, Section of Pharmacogenomics, CU-CVI
University of Colorado Cardiovascular Institute
Professor of Medicine (Cardiology)
University of Colorado School of Medicine
Aurora, Colorado, USA

Moderator:
Emily Highsmith, PharmD, BCCCP
Critical Care Clinical Pharmacist
MD Anderson Cancer Center
University of Texas
Houston, Texas, USA

The views and opinions expressed are those of the sponsor and do not necessarily reflect the views or opinions of SCCM. References to specific commercial entities, products, tests, procedures, opinions, resources, and information do not reflect SCCM’s review or endorsement.